Immuno-Oncology 2015: Sponsor Profiles
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.Our medicines are helping millions of patients around the world in their fight against cancer, cardiovascular disease, hepatitis B, HIV/AIDS and rheumatoid arthritis. The Bristol-Myers Squibb Foundation’s philanthropic programs seek to promote health equity and improve the health outcomes among populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world’s most vulnerable people.
Booth number: 2
Today's MSD is a global healthcare leader working to help the world be well. MSD is known as Merck in the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. MSD. Be well.
Booth number: 3
F. Hoffmann-La Roche Ltd.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients.
Booth number: 7
Immuno-oncology is a top priority for Merck and Pfizer. The global strategic alliance enables the companies to benefit from each other’s strengths and capabilities and explore the therapeutic potential of avelumab, an investigational anti-PD-L1 antibody initially developed by Merck. The alliance will jointly develop and commercialize avelumab and advance Pfizer’s PD-1 antibody. The companies will collaborate on up to 20 high priority immuno-oncology clinical development programs, including combination trials, which are expected to commence in 2015.
Booth number: 4
Celldex Therapeutics was founded on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development. Our pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers. This has created a leading pipeline including two candidates in pivotal trials, RINTEGA® in glioblastoma and glembatumumab vedotin in triple negative breast cancer, three additional clinical candidates (varlilumab, CDX-1401 and CDX-301) and a robust preclinical engine.
Booth number: 6
Personal Genome Diagnostics
Founded in 2010 by renowned scientists from Johns Hopkins, Personal Genome Diagnostics offers unparalleled solutions for comprehensive genomic analyses that assist researchers in identifying elusive cancer-related changes. With continuous research performed by our genomic and bioinformatics experts, we reliably identify and interpret genetic changes in tumor tissues and liquid biopsies.
Booth number: 5